Glucose intolerance in Chinese patients with chronic hepatitis C

Liang-Kung Chen, Shinn-Jang Hwang, Shih-Tzer Tsai, Ji-Jhong Luo, Shou-Dong Lee, Full-Young Chang

INTRODUCTION

Hepatitis C virus (HCV) infection has become a common worldwide medical problem. Patients with chronic HCV infection may develop various extrahepatic manifestations including cryoglobulinemia, glomerulonephritis, sialoadenitis and porphyria cutanea tarda. The association of chronic HCV infection and diabetes mellitus (DM) was first reported by Alison et al. in 1994. Based on case-control studies, the prevalence of DM had been reported in 21% to 50% of patients with chronic HCV infection, which was significantly higher than that in the general population or among patients with other diseases. Population surveys from western countries also demonstrated that chronic HCV infection was associated with a high incidence of DM. In addition, the prevalence of anti-HCV was significantly higher in patients with DM than in the general population.

The cause of a higher prevalence of DM in patients with chronic HCV infection remains unclear. Altered glucose metabolism has been well documented in patients with chronic liver diseases, especially in patients with liver cirrhosis. However, patients with HCV-related liver cirrhosis is associated with a significantly higher prevalence of DM than those cirrhotic patients with other etiologies. Furthermore, recipients of HCV-related liver transplantation were more likely to develop post-transplantation DM when compared to recipients with other etiologies. Therefore, HCV infection per se plays an important role in the pathogenesis of DM in patients with chronic HCV infection. Yet, analysis in previous studies rarely considered the confounding factors associated with DM development such as age, obesity and diabetic family history.

Interferon (IFN) has been widely used in the treatment of patients with chronic hepatitis C. Development of DM has also been reported as an adverse effect of IFN-α treatment in patients with chronic hepatitis C. In addition, exacerbation of previous diabetic control has been reported in chronic hepatitis B patients who received IFN-α treatment. The mechanism of IFN-related DM development or exacerbation of glycemic control remains unclear.

According to the American Diabetic Association (ADA) criteria, DM is diagnosed as repeated fasting plasma glucose ≥26 mg/dL, and impaired fasting glucose (IFG) is defined as the fasting plasma glucose >110 mg/dL and <126 mg/dL. Patients with IFG were reported to be prone to develop glucose intolerance. The purpose of this study was to evaluate the prevalence of diabetes were prone to develop glucose intolerance. To our knowledge, this is the first population-based report to confirm that interferon treatment to be an independent risk factor to develop glucose intolerance.

CONCLUSION: In conclusion, 34.6% of Chinese patients with chronic hepatitis C had glucose intolerance. Chronic hepatitis C patients who were older in age, obese, had previous IFN treatment history and had family history of diabetes were prone to develop glucose intolerance. To our knowledge, this is the first population-based report to confirm that interferon treatment to be an independent risk factor to develop glucose intolerance.

Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9(3): 505-508 http://www.wjgnet.com/1007-9327/9/505.htm

REFERENCES

1. Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9(3): 505-508.

2. World J Gastroenterol. 2003;9(3):505-508 World Journal of Gastroenterology Copyright © 2003 by The WJG Press ISSN 1007-9327
glucose intolerance (DM and IFG) in Chinese patients with chronic hepatitis C in Taiwan. In addition, risk factors associated with DM development such as age, body mass index (BMI), diabetic family history in first-degree relatives and previous IFN treatment were also evaluated to clarify the possible role of chronic HCV infection in association with the development of DM.

MATERIALS AND METHODS

Demographic data

From July 1999 to June 2001, we conducted a cross-sectional study by enrolling and following patients who were previously or newly diagnosed as chronic hepatitis C in the Office Clinics of Taipei Veterans General Hospital in Taiwan, Taiwan. The diagnosis of chronic hepatitis C was based on the presence of serum anti-HCV with or without histological confirmation. At least twice for more than 6 months, all patients had elevated serum alanine aminotransferase levels 1.5-fold above the upper limit of the normal value (>60 U/L). Patients who had positive serum hepatitis B surface antigens and chronic liver diseases were excluded.

According to the ADA diagnostic criteria, diagnosis of DM was established according to the documentation of DM in previous medical records and/or repeated fasting plasma glucose ≥10 mmol/L (126 mg/dL), and IFG was diagnosed with a FPG >110 mg/dL and ≤126 mg/dL. In this study, both patients with DM and IFG were categorized together as having glucose intolerance to compare them with patients with normal glucose tolerance.

The BMI and family history of DM were recorded for each patient during enrollment. The BMI was expressed as the body weight (in kilograms) divided by the square of the body length (in meter). The family history of diabetes was obtained from the patients themselves and was recorded as positive if their first-degree relatives had DM. Obesity was defined when BMI was ≥27 Kg/m2 in males and ≥25 Kg/m2 in females. Liver cirrhosis was diagnosed by either liver histology or by characteristic findings in abdominal sonography, computed tomography, celiac angiography and/or the presence of esophageal varices and ascites.

IFN treatment

We recorded details of patients who received IFN treatment, including various regimens of IFN-α2a, IFN-α2b, consensus IFN, subcutaneous injections three times a week, and long-acting pegylated IFNα-2a subcutaneous injections once a week with or without oral ribavirin for either 24 weeks or 48 weeks.

Biochemical data

Series of biochemical tests including serum alanine aminotransferase and fasting plasma glucose were measured by using an autoanalyzer (Hitachi sequential multiple autoanalyzer; Model 736, Tokyo, Japan). Antibodies to HCV were measured by using a second-generation enzyme autoanalyzer (Hitachi-736, Tokyo, Japan). Antibodies to HCV were measured by using a radioimmunoassay (Abbott Laboratories, Chicago, IL, USA). Aminotransferase and fasting plasma glucose were measured by using an autoanalyzer (Hitachi-736, Tokyo, Japan). Antibodies to HCV were measured by using a radioimmunoassay (Abbott Laboratories, Chicago, IL, USA).

Statistical analysis

Data in the text and tables are expressed as mean ± standard deviation (mean ± S.D.). Results were compared between groups depending on the type of data analyzed using the Chi-squared test, Student t-test or Mann-Whitney U-test. Stepwise multivariate logistic regression (SPSS 10.0, Chicago, IL, USA) was performed to evaluate the predictive variables associated with the presence of glucose intolerance in patients with chronic hepatitis C. For all tests, results with P values less than 0.05 were considered statistically significant.

RESULTS

General data of patients

Totally, 359 patients (212 males and 147 females) were enrolled in this study and completed their follow-up investigations in the Office Clinic for more than six months. The mean age of all patients was 58.1±13.0 years old (ranging from 22 to 85 years old). Among these patients, 112 (31.2 %) had a previous history of blood transfusion. Patients without a transfusion history had a past history of undisposable needle injections. None of these patients were intravenous drug abusers or under regular hemodiagnosis. Among all patients, 66 (18.4 %) of them had a family history of diabetes. The mean BMI of all patients was 24.0±3.5 Kg/m². Eighty-seven (24.2 %) patients were obese. One hundred and fifty patients had received a percutaneous liver biopsy. Clinical and histology-liver cirrhosis was identified in 75 patients (20.9 %). One hundred and twenty-three patients (34.3 %) had a prior history of IFN treatment with a mean duration of 3.3 years (ranging from 0.5 to 7 years) from completion of IFN treatment till enrollment.

Results of glucose intolerance

Among the 359 patients, 125 patients (34.6 %) had glucose intolerance, including 99 patients (27.6 %) with DM, and 26 patients (7.0 %) with IFG. The remaining 234 patients had normal fasting glucose. None of the 125 patients with glucose intolerance were diagnosed as type 1 DM. The mean age of chronic hepatitis C patients with glucose intolerance was significantly older than the age of those with normal fasting glucose (61.1±11.2 vs 56.6±13.6 years; P=0.001). The mean BMI of chronic hepatitis C patients with glucose intolerance was significantly higher than that of those with normal fasting glucose (24.5±3.7 vs 23.7±3.2 Kg/m²; P=0.024). Thirty-eight of the 125 (30.4 %) patients with glucose intolerance were obese, which was significantly higher than those with normal fasting glucose (53/235, 22.6 %, P=0.02). Chronic hepatitis C patients with glucose intolerance had a significantly higher rate of diabetic family history than those with normal fasting glucose (29.6 % vs 12.8 %, P<0.001, Table 1).

Table 1. Comparisons of demographic data between chronic hepatitis C patients with glucose intolerance* and normal fasting glucose

| Table 1. Comparisons of demographic data between chronic hepatitis C patients with glucose intolerance* and normal fasting glucose | Patients with glucose intolerance (n=125) | Patients with normal fasting glucose (n=234) | P value |
|---|---|---|---|
| Age | 61.1±11.2 | 56.6±13.6 | 0.001 |
| Sex (male:female) | 47:78 | 99:135 | 0.452 |
| Body mass index (Kg/m²) | 24.5±3.7 | 23.7±3.2 | 0.024 |
| Family history of DM (+:−) | 37.88 | 30.204 | <0.001 |
| Obesity (+:−) | 38:87 | 49:185 | 0.046 |
| Liver cirrhosis (+:−) | 28:97 | 47:187 | 0.706 |
| Previous interferon treatment (+:−) | 51:74 | 66:188 | 0.021 |

Denotes: Data were expressed as mean±S.D. * Patients with glucose intolerance included patients with diabetes mellitus and impaired fasting glucose by the diagnostic criteria of the American Diabetes Association.
**Data of IFN treatment**

One hundred and seventeen patients (32.6 %) had a previous history of IFN treatment. Among these, 117 patients, 44 patients were treated with consensus IFN 3 µg (n=14), 9 µg (n=17) or 15 µg (n=13) for 24 weeks, 29 patients were treated with IFNα-2b 3 million units (MU) three times a week for 24 weeks, 4 patients were treated with IFNα-2a 6 MU three times a week for 12 weeks followed by 3 MU three times a week for 36 weeks, and 7 patients were treated with IFNα-2b 3 MU three times a week for 48 weeks along with oral ribavirin (1 000 mg/day for patients who weighed less than 75 Kg, and 1 200 mg/day for those who weighed more than 75 Kg).

Twenty-seven patients were treated with pegylated IFNα-2a 180 µg once a week for 48 weeks, and 19 of them also received oral ribavirin treatment. Six patients received pegylated IFNα-2a 180 µg once a week and oral ribavirin for 24 weeks. In patients who had a previous history of IFN treatment, 42.7 % (50/117) were glucose intolerant, which was significantly higher than the 30.2 % (73/242) of those without a history of IFN treatment (P=0.021). Fifty-one patients out of a total of 125 patients (40.8 %) with glucose intolerance had a past history of IFN treatment, which was significantly higher than the 66 patients out of 234 patients (28.2 %) with normal fasting glucose (P=0.021). There was no significant difference in gender and in relation to the presence of cirrhosis between the two groups (Table 1).

**Table 2 Significant predictive variables of glucose intolerance in chronic hepatitis C patients using stepwise multivariate logistic regression analysis**

| Coefficient | Odds ratio | 95% CI | P value   |
|-------------|------------|--------|-----------|
| Age 57 years | 1.251      | 3.50   | 2.06-5.92 | <0.001    |
| Diabetic family history | 1.289 | 3.64 | 2.00-6.57 | <0.001    |
| Obesity | 0.576 | 1.78 | 1.05-3.03 | 0.034     |
| Previous interferon treatment | 0.803 | 2.23 | 1.34-3.72 | 0.002     |

Denotes: CI: confidence interval.

**DISCUSSION**

The close relationship between DM and chronic HCV infection has been reported in several previous studies although the exact pathogenesis remains unclear[1-11]. The age-adjusted population-based prevalence of type 2 DM and IFG in Taiwan was 5.9 % and 15.7 %, respectively[27,30]. According to our results, the prevalence of DM and IFG in patients with chronic hepatitis C was 27.6 % and 70.4 %, respectively. The prevalence of glucose intolerance (DM and IFG) was significantly higher than the age-matched normal population in Taiwan.

An altered glucose metabolism had been reported in patients with chronic liver diseases and liver cirrhosis[11]. However, patients with HCV-related chronic hepatitis and liver cirrhosis demonstrated a stronger correlation than those patients with other etiologies[5-11]. Patients with a viral infection alone such as cytomegalovirus, Coxsackie virus and mumps were reported to develop DM, but most of the reported cases were type 1 DM[31-33]. The pathogenesis of HCV-related DM remains mysterious.

Although the close relationship between DM and chronic HCV infection has been noted, the risk factors of DM including age, sex, the presence of family history of diabetes, BMI, liver cirrhosis, and previous history of IFN treatment has not been well investigated in previous case-control studies. In the general population, male gender, older age, obesity and the presence of family history of diabetes were well recognized as significant risk factors for the development of DM. According to our results, all these risk factors except the male gender remained independent risk factors associated with the presence of DM in chronic hepatitis C patients. These findings indicated that multiple factors may contribute to the development of DM in patients with chronic hepatitis C.

Of particular interest, our results showed significantly that previous IFN treatment was an independent risk factor for the development of glucose intolerance in patients with chronic hepatitis C. IFN had been widely used in the treatment of patients with chronic hepatitis C[12-16]. Development of DM or the exacerbation of previously stable glycemic control in diabetic patients had been reported as drug side effects in chronic hepatitis C patients who were receiving IFN treatment, but the mechanism of this phenomenon remains unknown[17-19]. The presence of islet cell autoantibodies had ever been reported in a chronic hepatitis C patient during IFN treatment[34]. Fabris et al reported that the development of DM during IFN treatment was resulted from the amplification of previously existing autoimmunity against pancreatic β cells[35]. However, a report contradicting these findings was published later[36].

Koivisto et al also postulated that impaired glucose tolerance was found in healthy volunteers who received IFN treatment, and this phenomenon may have resulted from the development of insulin resistance through the complex interaction between insulin and its counter-regulatory hormones[37]. However, by using a minimal model, IFN-α injection was reported to ameliorate the glucose tolerance in diabetic and non-diabetic patients with chronic HCV infection[38]. Our results showed that previous IFN therapy can be used significantly as an independent variable to predict the development of glucose intolerance in patients with chronic hepatitis C. Patients enrolled in our study received various forms of IFN with different dosages and durations. Therefore, further evaluations are needed to clarify the enigmatic association between IFN treatment and DM development in patients with chronic hepatitis C.

In conclusion, 34.6 % of patients with chronic hepatitis C were glucose intolerant. Chronic hepatitis C patients who were older in age, were obese, and had a previous history of IFN treatment as well as a family history of diabetes were prone to develop glucose intolerance. To our best knowledge, this is the first population-based report to confirm that interferon treatment to be an independent risk factor to develop glucose intolerance.

**ACKNOWLEDGEMENTS**

This study was supported by a grant (NSC ) from National Science Council, Taiwan. The authors wish to thank Miss Wei-Lin Chen for her assistance in blood collection, and Miss Rei-Hwa Lu for her laboratory assistance.

**REFERENCES**

1. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Ann Intern Med 1995; 123: 615-620
Hwang SJ, Lee SD, Li CP, Lu RH, Chan CY, Wu JC. Clinical study of cryoglobulinemia in Chinese patients with chronic hepatitis C. J Gastroenterol Hepatol 1997; 12: 513-517

Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC, Chang FY, Lee SD. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol 1998; 13: 475-479

Allison ME, Wregitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139

Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O’Rahilly S, Shore S, Torn BD, Alexander GJ. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-1063

Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Gastroenterol Hepatol 1998; 26: 30-33

Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333

Ozylkan E, Erbas T, Sremsk H, Telatar F, Kayhan B, Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 1994; 235: 283-284

Simro J, Jard R, Hernandez C, Mesa J, Genesca J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000

Kingston ME, Ali MA, Atiyeh M, Donnelly RJ. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 1984; 87: 668-694

Bigam DL, Pennington JJ, Carpenter A, Wanless IR, Hamming AW, Croxford R, Greg PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: a predictor of diabetes mellitus for patients after liver transplantation. Hepatology 2000; 32: 87-90

Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (Suppl 1): 635-638

Poynard T, Leroy V, Coharld M, Thevenot T, Mathurin P, Opolon P, Zariski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789

Farrell GC. Therapy of hepatitis C: interferon alfa-nl trials. Hepatology 1997; 26 (Suppl 1): 905-1005

Poynard T, Marcellin P, Lee SS, Niederau C, Minouk GS, Ideo G, Bain V, Heathcot J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998; 352: 1426-1432

M Hutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodan ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492

Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasaki S, Sakamoto M, Nishioji K, Kabagoh T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 383-391

Fattovich G, Giustina G, Favaro G, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38-47

Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, Dib SA. Exacerbation of type 2 diabetes mellitus during interferon alfa therapy for chronic hepatitis B. Lancet 1994; 343: 224

The Expert Committee of the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197

Tsai ST, Li CL, Chen CH, Chou P. Community-based epidemiological study of glucose tolerance in Kin-Chen, Kinmen: support for a new intermediate classification. J Clin Epidemiol 2000; 53: 505-510

National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057

Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res 1995; 15: 611-666

Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY. A randomized, double-blind controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. Am J Gastroenterol 1999; 94: 2496-2500

Hwang S, Lee S, Chu C, Lu R, Chang F. An open-label trial of consensus interferon 15 mcg in the treatment of Chinese patients with chronic hepatitis C. Hepatol Res 2001; 19: 284-293

Zeuzem S, Feinman SV, Rauenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brundaj M. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672

Tai TY, Yang CL, Chang CJ. Epidemiology of diabetes mellitus among adults in Taiwan, ROC. J Med Assoc Thailand 1997; 80 (Suppl 2): 42-48

Lin JD, Shieh WB, Huang MJ, Huang HS. Diabetes mellitus and hypertension based on the family history and 2-h postprandial blood sugar in the Ann-Lo district (northern Taiwan). Diabet Res Clin Pract 1993; 20: 75-85

Lu FH, Yang YC, Wu JS, Wu CH, Chang CJ. A population-based study of the prevalence and associated factors of diabetes in southern Taiwan. Diabet Med 1998; 15: 564-572

Chang C, Lu F, Yang YC, Wu JS, Wu TJ, Chen MS, Chuang LM, Tai TY. Epidemiologic study of type 2 diabetes in Taiwan. Diabet Res Clin Pract 2000; 50 (Suppl 2): 549-559

Forrest JM, Menser MA, Burgess JA. High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2: 332-334

King MD, Shaikh A, Bidwell D, Voller A, Banatvala JE. Coxsackie-B virus-specific IgM responses in children with insulin-dependent (juvenile onset, type I) diabetes mellitus. Lancet 1983; 1: 1397-1399

Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1998; 2: 1-4

Campbell S, Mclaren ED, Danesh BJ. Rapidly reversible increase in insulin requirement with interferon. Brit Med J 1996; 316: 92

Fabris P, Betterle C, Greggi G, Zanchetta R, Bosi E, Biasin MR, de Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514-517

Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-α therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 1177-1181

Kolvista VA, Canteli K, Pelkonen R. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-647

Konrad T, Vicini P, Zeuzem S, Toffolo G, Breim D, Lornach J, Herrmann G, Wittmann D, Lenz T, Kusterer K, Teuber G, Cobelli C, Usadel KH. Interferon-α improves glucose tolerance in diabetic and non-diabetic patients with HCV-infected liver disease. Exp Clin Endocrinol Diabetes 1999; 107: 343-349

Edited by Xu XQ